Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Catechins are extensively used in health care treatments. Nevertheless, there is scarce information about the feasibility of local administration with polyphenols for bone regeneration therapy, possibly due to lack of effective delivery systems. Here we demonstrated that the epigallocatechin-3-gallate-conjugated gelatin (EGCG/Gel) prepared by an aqueous chemical synthesis using 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-morpholinium chloride (DMT-MM) gradually disintegrated with time and facilitated bone formation in a critical size defect of a mouse calvaria. Conjugation of EGCG with the Gel generated cross-linking between the two molecules, thereby leading to a retardation of the degradation of the EGCG/Gel and to a delayed release of EGCG. The prepared EGCG/Gels represented significant osteogenic capability compared with that of the uncross-linked Gel and the cross-linked Gel with uncombined-EGCG. In vitro experiments disclosed that the EGCG/Gel induced osteoblastogenesis of a mouse mesenchymal stem cell line (D1 cells) within 14 days. Using fluorescently-labeled EGCG/Gel, we found that the fraction of EGCG/Gel adsorbed onto the cell membrane of the D1 cells possibly via a Gel-cell interaction. The interaction might confer the long-term effects of EGCG on the cells, resulting in a potent osteogenic capability of the EGCG/Gel in vivo. These results should provide insight into local controlled release of polyphenols for bone therapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490544PMC
http://dx.doi.org/10.3390/ijms160614143DOI Listing

Publication Analysis

Top Keywords

local controlled
8
controlled release
8
bone formation
8
polyphenols bone
8
osteogenic capability
8
egcg/gel
6
release polyphenol
4
polyphenol conjugated
4
conjugated gelatin
4
gelatin facilitates
4

Similar Publications

Purpose: Glioblastoma (GBM) remains one of the most aggressive primary brain tumors with poor survival outcomes and a lack of approved therapies. A promising novel approach for GBM is the application of photodynamic therapy (PDT), a localized, light-activated treatment using tumor-selective photosensitizers. This narrative review describes the mechanisms, delivery systems, photosensitizers, and available evidence regarding the potential of PDT as a novel therapeutic approach for GBM.

View Article and Find Full Text PDF

Introduction: Amivantamab plus lazertinib significantly improved progression-free and overall survival versus osimertinib in patients with previously untreated, EGFR-mutant advanced NSCLC. EGFR-targeted therapies are associated with dermatologic adverse events (AEs), which can affect quality of life (QoL). COCOON was conducted to assess prophylactic management and improve treatment experience.

View Article and Find Full Text PDF

Background: Gynecologic enhanced recovery after surgery (ERAS) pathways have been developed to reduce postoperative narcotic use through multimodal pain management. While incisional injection of local anesthetic is standard practice, regional nerve blockades using liposomal agents are emerging as a promising adjunct technique for post-laparoscopy pain. Current data are conflicting regarding the benefits of regional nerve blocks on postoperative pain after laparoscopic hysterectomy.

View Article and Find Full Text PDF

Bioorthogonal chemistry that can be controlled through near-infrared (NIR) light is a promising route to therapeutics. This study proposes a method to intracellularly photoactivate prodrugs using plasmonic gold nanostars (AuNSt) and NIR irradiation. Two strategies are followed.

View Article and Find Full Text PDF

Background And Purpose: Parkinson's disease (PD), a prevalent neurodegenerative disorder characterized by motor impairments, frequently accompanied by neuropsychiatric symptoms that significantly impair daily functioning and quality of life. The present study aimed to assess the efficacy of botulinum toxin A (BTX-A) in alleviating neuropsychiatric symptoms among PD patients.

Methods: This is an open-label, nonrandomized controlled trial.

View Article and Find Full Text PDF